Download PDF
Semin Vasc Med 2003; 03(3): 303-314
DOI: 10.1055/s-2003-44640
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Oral Anticoagulant Therapy in Venous Thromboembolism

Benilde Cosmi, Gualtiero Palareti
  • Cardiovascular Department, Division of Angiology, S. Orsola-Malpighi University Hospital, Bologna, Italy
Further Information

Publication History

Publication Date:
21 November 2003 (online)

    Permissions and Reprints

ABSTRACT

The main objective of treatment of venous thromboembolism (VTE) is the prevention of the extension, embolization, and recurrence of thrombosis. The long-term aim is to prevent late recurrences and the post-thrombotic syndrome. Heparin and oral anticoagulants (OACs) have been the cornerstones of VTE treatment in the last 30 years. Low molecular weight heparins (LMWHs) have been introduced more recently in the treatment of the acute phase of VTE, and they have allowed the home treatment of deep vein thrombosis (DVT) in selected cases. The optimal duration of OAC therapy after VTE is still controversial. Several studies have been conducted, and several are ongoing with the aim to stratify patients into risk categories for recurrence. Patients at high risk are candidates for long-term oral anticoagulation as the benefits of extended oral anticoagulation would outweigh the risk of bleeding. Patients are currently stratified into risk categories on the basis of clinical characteristics of the VTE event: (1) first or recurrent event; (2) idiopathic or due to a transient risk factor such as surgery, trauma, hormonal therapy, or immobilization; (3) presence of active cancer; (4) location (proximal DVT and/or pulmonary embolism, PE, or distal DVT); and (5) presence of known hereditary or acquired thrombophilia. Patients with distal VTE or VTE due to a transient risk factor are at a low risk of recurrence and short-term anticoagulation is indicated (3 months). Patients with an idiopathic event or with known thrombophilic defects such as FV Leiden or the G20210A prothrombin mutation are candidates for a longer course of therapy (6 months). Patients with cancer, antiphospholipid antibodies syndrome, recurrent idiopathic event, antithrombin deficiency, protein C or protein S deficiency, homozygosity for FV Leiden, and double heterozygosity are candidates for extended long-term anticoagulation. More recently, studies have indicated that other factors such as D-dimer levels after the discontinuation of OAC therapy or the residual vein thrombosis could be additional predictive factors for recurrences. In patients with VTE and cancer, oral anticoagulation poses a higher risk of bleeding, and such patients are more prone to recurrences. Alternative treatment with LMWH could be safer and more effective in these patients.

KEYWORDS

Venous thromboembolism - oral anticoagulants - deep vein thrombosis

REFERENCES

  • 1 Ansell J E. Oral anticoagulant therapy-50 years later.  Arch Intern Med . 1993;  153 586-596
    CrossrefPubMedGoogle Scholar
  • 2 Stenflo J, Fernlund P, Egan W, Roepstortf P. Vitamin K dependent modifications of glutamic acid residues in prothrombin.  Proc Natl Acad Sci USA . 1974;  71 2730-2733
    PubMedGoogle Scholar
  • 3 Nelsestuen G L, Zytkovicz T H, Howard J B. The mode of action of vitamin K: identification of gamma carboxyglutamic acid as a component of prothrombin.  J Biol Chem . 1974;  249 6347-6350
    PubMedGoogle Scholar
  • 4 Barrit D W, Jordan S C. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial.  Lancet . 1960;  1 1309-1312
    PubMedGoogle Scholar
  • 5 Hirsh J, Dalen J E, Anderson D R. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range.  Chest . 1998;  114 445S-469S
    CrossrefPubMedGoogle Scholar
  • 6 Gallus A, Jackman J, Mills W, Tillett J, Wicherley A. safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.  Lancet . 1986;  6 1293-1296
    PubMedGoogle Scholar
  • 7 Hull R D, Raskob G E, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal vein thrombosis.  N Engl J Med . 1990;  322 1260-1264
    PubMedGoogle Scholar
  • 8 Harrison L, Johnston M, Massicotte M P. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.  Ann Intern Med . 1997;  126 133-136
    PubMedGoogle Scholar
  • 9 Crowther M A, Ginsberg J B, Kearon C, Harrison L, Johnson J, Massicotte M P, Hirsh J. A randomized trial comparing 5-mg and 10-mg warfarin loading doses.  Arch Intern Med . 1999;  159 46-48
    CrossrefPubMedGoogle Scholar
  • 10 Hull R D, Delmore T, Genton E. Warfarin sodium versus low dose heparin the long term treatment of venous thrombosis.  N Engl J Med . 1979;  302 855-858
    PubMedGoogle Scholar
  • 11 Hull R D, Delmore T, Carter C. Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis.  N Engl J Med . 1982;  306 189-194
    PubMedGoogle Scholar
  • 12 Hull R D, Hirsh J, Jay R M. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.  N Engl J Med . 1982;  307 1676-1681
    PubMedGoogle Scholar
  • 13 Doyle D J, Turpie A G, Hirsh J. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: a randomized trial.  Ann Intern Med . 1987;  107 441-445
    PubMedGoogle Scholar
  • 14 Brandjes D PM, Hejboer H, Buller H R. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis.  N Engl J Med . 1992;  327 1485-1489
    CrossrefPubMedGoogle Scholar
  • 15 Levine M, Gent M, Hirsh J. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis.  N Engl J Med . 1996;  334 677-681
    CrossrefPubMedGoogle Scholar
  • 16 Koopman M MW, Prandoni P, Piovella F. Treatment of venous thrombosis with intravenous heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home.  N Engl J Med . 1996;  334 682-687
    CrossrefPubMedGoogle Scholar
  • 17 Ten Cate W J, Buller H R, Gent M. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism by The Columbus Investigators.  N Engl J Med . 1997;  337 657-662
    CrossrefPubMedGoogle Scholar
  • 18 Simonneau G, Sors H, Charbonnier B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.  N Engl J Med . 1997;  337 663-669
    CrossrefPubMedGoogle Scholar
  • 19 Ginsberg J, Hirsh J. Use of antithrombotic agents during pregnancy.  Chest . 1998;  114 524S-530S
    PubMedGoogle Scholar
  • 20 Hyers T M, Agnelli G, Hull R D, Morris T A, Samama M, Tapson V, Weg J G. Antithrombotic therapy for venous thromboembolic disease.  Chest . 2001;  119 176S-193S
    CrossrefPubMedGoogle Scholar
  • 21 Garabedian-Ruffalo S M, Gary D R, Sax M J. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic.  Am J Hosp Pharm . 1985;  42 304-308
    PubMedGoogle Scholar
  • 22 Cortelazzo S, Finazzi G, Viero P. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prostheses attending an anticoagulation clinic.  Thromb Haemost . 1993;  69 316-320
    PubMedGoogle Scholar
  • 23 Wilt V M, Gums J G, Ahmed O I. Pharmacy operated anticoagulation service: improved outcomes in patients on warfarin.  Pharmacotherapy . 1995;  15 732-739
    PubMedGoogle Scholar
  • 24 Chiquette E, Amato M G, Bussey H I. Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes and health care costs.  Arch Intern Med . 1998;  158 1641-1647
    CrossrefPubMedGoogle Scholar
  • 25 Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin.  J Clin Pathol . 1993;  46 299-303
    CrossrefPubMedGoogle Scholar
  • 26 Poller L, Shiach C R, MacCallum P. The European Concerted Action on Anticoagulation (ECAA): multicentre randomized study of computerized anticoagulant dosage.  Lancet . 1998;  352 1505-1509
    CrossrefPubMedGoogle Scholar
  • 27 Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori A G. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment).  Haematologica . 2001;  86 1060-1070
    PubMedGoogle Scholar
  • 28 Coon W W, Willis P W. Recurrence of venous thromboembolism.  Surgery . 1973;  73 823-827
    PubMedGoogle Scholar
  • 29 Lagerstedt C I, Fagher B O, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis.  Lancet . 1985;  2 515-518
    PubMedGoogle Scholar
  • 30 O'Sullivan E F. Duration of anticoagulant therapy in venous thromboemebolism.  Med J Aust . 1972;  2 1104-1107
    PubMedGoogle Scholar
  • 31 Holmgren K, Andersson G, Fagrell B. 1 month versus 6 months therapy with oral anticoagulants after symptomatic deep vein thrombosis.  Acta Med Scand . 1985;  218 279-284
    PubMedGoogle Scholar
  • 32 Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis-a randomized study.  Acta Med Scand . 1985;  217 547-552
    PubMedGoogle Scholar
  • 33 Fennerty A G, Dolben J, Thomas P, Backhouse G, Bentley D P, Campbell I A, Routledge P A. A comparison of 3 and 6 weeks' anticoagulation in the treatment of venous thromboembolism.  Clin Lab Haematol . 1987;  9 17-21
    PubMedGoogle Scholar
  • 34 Sudlow M F, Campbell I A, Angel J H. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism.  Lancet . 1992;  340 873-876
    PubMedGoogle Scholar
  • 35 Schulman S, Rhedin A S, Lindmarker P. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism.  N Engl J Med . 1995;  332 1661-1665
    CrossrefPubMedGoogle Scholar
  • 36 Schulman S, Wiman B, Duration of Anticoagulation (DURAC) trial study group. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost .  1996;  75 607-611
    PubMedGoogle Scholar
  • 37 Crowther M A, Roberts J, Roberts R. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study.  Thromb Haemost . 2001;  85 390-394
    PubMedGoogle Scholar
  • 38 Schulman S, Granqvist S, Holmstrom M. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism.  N Engl J Med . 1997;  336 393-398
    CrossrefPubMedGoogle Scholar
  • 39 Prandoni P, Lensing A WA, Cogo A. The long term clinical course of acute deep vein thrombosis.  Ann Intern Med . 1996;  125 1-7
    CrossrefPubMedGoogle Scholar
  • 40 Levine M N, Hirsh J, Gent M. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.  Thromb Haemost . 1995;  74 606-611
    PubMedGoogle Scholar
  • 41 Kearon C, Gent M, Hirsh J. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thrombosis.  N Engl J Med . 1999;  340 901-907
    PubMedGoogle Scholar
  • 42 Agnelli G, Prandoni P, Santamaria M G. Three months versus one year of oral anticoagulation therapy for idiopathic deep venous thrombosis.  N Engl J Med . 2001;  345 165-169
    PubMedGoogle Scholar
  • 43 Pinede L, Ninet J, Duhaut P. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf-vein thrombosis.  Circulation . 2001;  103 2453-2460
    CrossrefPubMedGoogle Scholar
  • 44 Hutten B A, Prins M H. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism (Cochrane Review). In: Cochrane Library Oxford: Update Software 2003 issue 1
    Google Scholar
  • 45 Ridker P M, Goldhaber S Z, Danielson E. Long-term, low intensity warfarin therapy for the prevention of recurrent venous thromboembolism.  N Engl J Med . 2003;  348 1425-1434
    CrossrefPubMedGoogle Scholar
  • 46 Bauer K A. Management of patients with hereditary defects predisposing to thrombosis including pregnant women.  Thromb Haemost . 1995;  74 94-100
    PubMedGoogle Scholar
  • 47 Hirsh J, Lee A. How we diagnose and treat deep vein thrombosis.  Blood . 2002;  99 3102-3110
    CrossrefPubMedGoogle Scholar
  • 48 Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost .  2002;  87 7-12
    PubMedGoogle Scholar
  • 49 Piovella F, Crippa L, Barone M. Normalization of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with DVT recurrence and new thrombosis.  Haematologica . 2002;  87 515-522
    PubMedGoogle Scholar
  • 50 Prandoni P, Lensing A W, Prins M H. Residual venous thrombosis as a predictive factor for recurrent venous thromboembolism.  Ann Intern Med . 2002;  137 955-960
    PubMedGoogle Scholar
  • 51 Das S K, Cohen A T, Edmondson R A, Melissari E, Kakkar V V. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial.  World J Surg . 1996;  20 521-526
    CrossrefPubMedGoogle Scholar
  • 52 Gonzalez-Farajardo J A, Arreba E, Castrodeza J. Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.  J Vasc Surg . 1999;  30 283-290
    CrossrefPubMedGoogle Scholar
  • 53 Hamann H. Rezidivprophylaxe nach Phlebothrombose-orale Antikoagulatin oder niedermolekulares Heparin subkutan [Low molecular weight heparin versus coumarin in the prevention of recurrence after deep vein thrombosis].  Vasomed . 1998;  10 133-136
    PubMedGoogle Scholar
  • 54 Lopaciuk S, Bielska-Falda H, Noszczyk W. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.  Thromb Haemost . 1999;  81 26-31
    PubMedGoogle Scholar
  • 55 Lopez-Beret P, Orgaz A, Fontcuberta J, Doblas M, Martinez A, Lozano G, Romero A. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis.  J Vasc Surg . 2001;  33 77-90
    PubMedGoogle Scholar
  • 56 Pini M, Aiello S, Manotti C. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis.  Thromb Haemost . 1994;  72 191-197
    PubMedGoogle Scholar
  • 57 Veiga F, Escriba A, Maluenda M P. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.  Thromb Haemost . 2000;  84 559-564
    PubMedGoogle Scholar
  • 58 van der Heijden J F, Hutten B A, Büller H R, Prins M H. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Review). In: The Cochrane Library. Oxford: Update Software 2002 issue 3
    Google Scholar
  • 59 Palareti G, Manotti C, D'Angelo A. Thrombotic events during anticoagulant treatment: results of the inception cohort, prospective, collaborative ISCOAT study.  Thromb Haemost . 1997;  78 1438-1443
    PubMedGoogle Scholar
  • 60 Hutten B A, Prins M H, Gent M, Ginsberg J, Tijssen J, Buller H R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized Ratio: a retrospective analysis.  J Clin Oncol . 2000;  18 3078-3083
    PubMedGoogle Scholar
  • 61 Palareti G, Legnani C, Lee A. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy.  Thromb Haemost . 2000;  84 805-810
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Prandoni P, Lensing A W, Piccioli A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.  Blood . 2002;  100 3484-3488
    CrossrefPubMedGoogle Scholar
  • 63 Meyer G, Marjanovic Z, Valcke J. Comparison of low-molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.  Arch Intern Med . 2002;  162 1729-1735
    CrossrefPubMedGoogle Scholar
  • 64 Monagle P, Michelson A D, Bovill E, Andrew M. Antithrombotic therapy in children.  Chest . 2001;  119 344S-370S
    CrossrefPubMedGoogle Scholar
  • 65 Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant.  Am J Pediatr Hematol Oncol . 1990;  12 95-104
    CrossrefPubMedGoogle Scholar
  • 66 Andrew M, Vegh P, Johnston M. Maturation of the hemostatic system during childhood.  Blood . 1992;  80 1998-2005
    PubMedGoogle Scholar
  • 67 Streif W, Andrew M, Marzinotto V. Analysis of warfarin therapy in paediatric patients: a prospective cohort study.  Blood . 1999;  94 3007-3014
    PubMedGoogle Scholar
  • 68 Andrew M, Marzinotto V, Brooker L. Oral anticoagulant therapy in pediatric patients: a prospective study.  Thromb Haemost . 1994;  71 265-269
    PubMedGoogle Scholar